18 results about "Drug study" patented technology

The embodiment of the invention provides a multi-level early warning method and system for faults of intelligent equipment and a related device. The method comprises the following steps: receiving edge node data from edge nodes of a laboratory; according to the historical operation data of the plurality of intelligent devices, the environment baseline of the laboratory and the fault records of the plurality of intelligent devices, generating healthy operation thresholds corresponding to the plurality of intelligent devices; performing weighted scoring on the edge node data, and dividing risk levels of the plurality of intelligent devices according to weighted scores and a health operation threshold value; executing an early warning strategy according to the risk level grading; and establishing an association relationship among the fault events of the plurality of intelligent devices, the experiment batch information and the experiment environment change, and dynamically adjusting a healthy operation threshold according to the association relationship. Therefore, through multi-dimensional sensing and dynamic execution of the early warning strategy, active prevention and grading disposal of equipment faults are realized, the real-time performance of safety management of the drug laboratory is effectively improved, and accurate monitoring of early warning of the laboratory is realized.

The present invention discloses a content analysis and extraction method, system and storage medium of a drug experiment document. The method comprises obtaining the first text of the corresponding drug experiment document, searching and matching the contents of each cell of a keyword, and querying the data format to which the keyword belongs if the keyword is matched; otherwise, retrieving the approximate dictionary table for matching, and obtaining the data format to which the corresponding keyword belongs for the matched approximate word; according to the data format, starting from the cell where the keyword or the approximate word is located, querying the data format in each cell in the same column or row, and obtaining the distribution area of ​​the cells having the same data format as the keyword; finally, obtaining the table type and the corresponding data value of each keyword according to the distribution area. The method can realize the analysis and extraction of data under the specified category or keyword of various types of tables in the drug experiment document, and can be used for subsequent rearrangement and induction into a new record table.

Methods, systems, and computer-readable media for rapid event voice documentation are provided herein. The rapid event voice documentation system captures verbalized orders and actions and translates that unstructured voice data to structured, usable data for documentation. The voice data captured is tagged with metadata including the name and role of the speaker, a time stamp indicating a time the data was spoken, and a clinical concept identified in the data captured. The system automatically identifies orders (e.g., medications, labs and procedures, etc.), treatments, and assessments / findings that were verbalized during the rapid event to create structured data that is usable by a health information system and ready for documentation directly into an EHR. The system provides all of the captured data including orders, assessment documentation, vital signs and measurements, performed procedures, and treatments, and who performed each, available for viewing and interaction in real time.

The present application relates to the technical field of machine learning, and particularly relates to a preclinical drug experiment quality evaluation method based on machine learning, comprising: obtaining a plurality of experiment samples, each experiment sample comprising a dose level and an observation value of at least one biological index; determining a trend residual of each biological index of each experiment sample; determining a biological index evaluation weight sequence composed of quality evaluation weights of all biological indexes; determining a composite distance between any two experiment samples; determining a quality evaluation index of each experiment sample; and evaluating the quality of preclinical drug experiments based on the quality evaluation index of each experiment sample. By constructing a dose effect trend function, combining the trend residual and the weight, establishing a composite distance model fusing pharmacological trends, realizing adaptive selection of neighborhood parameters, improving the accuracy and stability of anomaly detection, overcoming the limitations of traditional machine learning LOF algorithm, and enhancing the evaluation reliability.

The present invention provides a microfluidic device for tumor organoid culture and drug experiments and a method of use, belonging to the technical field of microfluidic devices. It includes a main body and two rotating shafts, the two rotating shafts are respectively rotatably connected to the top of the main body, and also includes a placement mechanism, the placement mechanism is arranged on the top of the two rotating shafts, and the placement mechanism includes two L-shaped frames. The present invention arranges the first microfluidic chip and the second microfluidic chip to be connected through a connecting tube, thereby reducing the phenomenon of the connection between the first microfluidic chip and the second microfluidic chip being loosened due to twisting, stretching or squeezing during long-term use of the connecting tube, and at the same time improves the stability of the connection between the first microfluidic chip and the second microfluidic chip, thereby reducing the loss of experimental samples and reagents due to internal liquid leakage between the first microfluidic chip and the second microfluidic chip, and the probability of contamination of the entire experimental device and the environment.

The invention discloses application of betrixaban or pharmaceutically acceptable salt thereof in preparation of antiviral drugs. Drug screening and in-vitro drug experiments find that betrixaban or pharmaceutically acceptable salts thereof can inhibit virus replication and infection ability, and can block virus-induced syncytial bodies, so that cell death caused by the syncytial bodies is reduced. In addition, the betrixaban or the pharmaceutically acceptable salt thereof provided by the invention has broad-spectrum antiviral activity, and also has the characteristics of safety and high efficiency.

The utility model discloses a high-precision electronic analytical balance for medicine experiments, and relates to the field of medicine experiments. The high-precision electronic analytical balance for the drug experiment comprises a balance body on which a scale pan is mounted, and further comprises four limiting columns which are fixedly connected to the balance body and surround the outer side of the scale pan in a rectangular shape; the windproof cover is arranged on the outer sides of the four limiting columns in a sleeving manner; according to the utility model, through the arrangement of the four limiting columns, the windproof cover can be guided when the windproof cover is covered on the outer side of the scale pan, so that the situation that the weighing accuracy is influenced due to the fact that the windproof cover touches medicines due to hand shaking of a worker when the larger medicines are weighed, and the medicines are displaced is avoided; meanwhile, when a worker accidentally touches the windproof cover, the windproof cover can be prevented from moving to impact the medicine, the economic loss caused by falling of the windproof cover and the medicine can be avoided, and the stability of the windproof cover is effectively improved.

The invention discloses an application of betrixaban or a pharmaceutically acceptable salt thereof. Drug screening and in-vitro drug experiments find that betrixaban or pharmaceutically acceptable salts thereof can inhibit virus replication and infection ability, and can block virus-induced syncytial bodies, so that cell death caused by the syncytial bodies is reduced. In addition, the betrixaban or the pharmaceutically acceptable salt thereof provided by the invention has broad-spectrum antiviral activity, and also has the characteristics of safety and high efficiency.

The utility model discloses a thermostatic reaction bath for medicine experiments, which comprises a case, a machine body is mounted at the rear end of the case, a console is mounted above the machine body, and a lifting rod is mounted at the top end of the case. According to the bottle blocking rod for the bottle inspection machine, a worker can turn over the box door upwards, the box door can rotate to drive the installation rod fixedly connected with one end to rotate, the rotating gear fixedly connected with the outer surface of the installation rod rotates in the groove, and the rotating gear can rotate in the groove through mutual penetration of the groove and the interior of the machine box; a rotating gear can rotate to drive a storage box horizontally below to slide forwards, the storage box slides outwards from the interior of a storage box, meanwhile, a water scraping plate fixedly connected with the bottom end of the storage box slides to scrape away water stains scattered in a machine box, workers can conveniently take the stored utensils, and meanwhile the working efficiency is improved. And scattered water spots can be removed.

The invention provides a microfluidic device for tumor organoid culture and drug experiments and a use method, and belongs to the technical field of microfluidic devices. Comprising a main body and two rotating shaft columns, the two rotating shaft columns are rotationally connected to the top of the main body, the device further comprises a placing mechanism, the placing mechanism is arranged at the tops of the two rotating shaft columns, and the placing mechanism comprises two L-shaped frames. The first micro-fluidic chip and the second micro-fluidic chip are communicated through the connecting pipe, so that the phenomenon of liquid leakage caused by looseness of the joint of the first micro-fluidic chip and the second micro-fluidic chip due to distortion, stretching or extrusion in the long-time use process of the connecting pipe is reduced; meanwhile, the connection stability of the first micro-fluidic chip and the second micro-fluidic chip is improved, so that the loss of experimental samples and reagents caused by leakage of liquid in the first micro-fluidic chip and the second micro-fluidic chip and the probability of pollution to the whole experimental device and the environment are reduced.

The present invention relates to an immunodeficient non-human animal where endogenous drug metabolising enzymes and transcription factors are substantially inactivated. In some aspects of the invention, the animal expresses human drug metabolising enzymes and associated transcription factors. There is also provided related methods of generating the animal of the invention. Additionally, there is provided methods of performing preclinical drug studies using the animal of the invention.

The utility model relates to the technical field of medicine experiment detection devices, and provides a tumor organ and medicine experiment detection device which comprises a support and side plates, the support comprises the side plates, a conveying structure, a feeding structure, a detection structure and a collecting box, the side plates are arranged on the two sides of the top end of the support, the conveying structure is arranged in the support, and the collecting box is arranged in the conveying structure. A feeding structure is arranged on one side of the support, and a detection structure is arranged on one side of the feeding structure. By arranging the feeding structure, a liquid medicine bottle is placed in the charging barrel, a first rotating shaft rotates to drive a second bevel gear to enable a first bevel gear to drive a spiral blade to rotate, and therefore the spiral blade drives a discharging pipe to enable the liquid medicine bottle to rotate in the charging barrel; and the liquid medicine bottles are conveyed to the bottom of the charging barrel and output to the conveying belt from the discharging pipe, so that the liquid medicine bottles are rotated and shaken while feeding of the liquid medicine bottles is facilitated, medicine in the liquid medicine bottles shakes more uniformly, and detection is facilitated.

The invention discloses a multi-modal fusion-based behavior detection device for an experimental animal after medicine taking. The device is composed of a data acquisition module, a data processing module, a behavior judgment module and a report generation module. According to data acquisition, experimental animal behavior and pressure data are synchronously acquired through a multispectral camera and a thin film pressure sensor, and a hardware-level timestamp protocol is adopted to align multi-modal signals; the data processing module extracts skeleton key points, motion trails and pressure distribution characteristics in the image; the behavior judgment module performs behavior classification on the multi-modal features based on a machine learning classifier; and the report generation module calls a large language model to automatically generate behavior statistics and a behavior report. Through multi-modal data fusion and intelligent analysis, the problems that manual recording is high in subjectivity and low in efficiency are solved, the method has the advantages of being high in behavior classification accuracy, high in data synchronization precision and capable of automatically generating an experimental report, and the efficiency and reliability of a medicine experiment are remarkably improved.

The utility model relates to the technical field of laboratory equipment, in particular to movable ventilation equipment for a medicine laboratory. According to the ventilation cabinet, the first air outlet adjusting assembly and the second air outlet adjusting assembly are arranged in the ventilation cabinet, the problem that the inclination angle of an air curtain cannot be adjusted through an existing ventilation device can be effectively solved, and the first air outlet in the first air outlet adjusting assembly is in linkage with the baffle through the connecting plate and the connecting rod; the inclination angle of the first air outlet can be adjusted by moving the baffle to form an obliquely downward air curtain, and in addition, the angle of the second air outlet can be adjusted by rotating the knob to form an obliquely upward air curtain, so that an experimenter can freely adjust the inclination angle of the first air outlet and the inclination angle of the second air outlet according to own needs; and the intersection of the air curtains is always located on the front side of the experiment position, so that an experimenter can perform experiment operation at different positions of the experiment cavity, and the safety of the experimenter can be better protected.

Autoclave for sterilization in pharmaceutical laboratories

The invention provides a medicine experiment simulation system and method and electronic equipment, and relates to the technical field of analog simulation, the system can perform virtualization modeling on a medicine experiment process, the medicine experiment process can be restored through medicine experiment simulation equipment, research and development personnel can break through space-time limitation, and the research and development efficiency is improved. When research and development inspiration appears, the medicine experiment simulation system can be used for simulation at any time, so that the safety of research and development personnel is improved, a complex preparation process in a real medicine experiment process is avoided, and the research and development efficiency of the research and development personnel is also improved.

The invention relates to the technical fields of Health Management, Medical Informatics, and Artificial Intelligence; it concerns e-HEMAP (Electronic Hospital Infection Cost Analysis Program), an expert decision support system that enables the simultaneous analysis of structured data within Hospital Information Management Systems (HIMS) and unstructured clinical data such as physician / nurse summaries, consultation and report texts using Natural Language Processing (NLP) and Big Language Models (LLM); the proactive prediction of Healthcare-Associated Infection (HAI) risk before clinical symptoms and diagnostic criteria emerge; and the reporting of direct and indirect additional costs associated with these infections at macro and micro levels by separating them from the patient's main diagnostic costs at the automation level. The invention also relates to the system's working method. The system in question comprises an Input Layer (100) where clinical data is collected, a Communication Layer (110) which ensures secure data transmission, a Data Lake Architecture (120) where data is stored, and a Processing Layer (130) that performs semantic scanning with an LLM architecture. The system also includes an NLP Analysis Unit (210) that distinguishes negative expressions in free text, a Filtering Unit (220) that clarifies parameters by filtering data, and ICD-10, SNOMED-CT, TC.The system includes the Matching / Evaluation Unit (230), which matches the Ministry of Health National SHIE Surveillance Diagnostic Guide with SUT, CDC / NHSN diagnostic criteria; the Decision Mechanism (240), which generates proactive alerts before clinical signs and diagnostic criteria appear using dynamic scoring and rule-based logic; the Cost Analysis Module (250), which automatically separates the costs of additional drugs, laboratory / radiology tests, consultations, medical consumables and materials, other interventional procedures and additional hospitalization days from the main diagnostic costs; and the e-HEMAP Cost Analysis Component (350). The system also includes the Billing Unit (440), which prepares consolidated invoice printouts, and the Management and Approval Mechanism (490), where data is submitted for EKK approval and external system integrations are provided.

The purpose of embodiments disclosed in the present specification is to provide an apparatus and a method for selecting, from among a large number of organoids, an organoid suitable for a drug experiment on a specific gene. In addition, the purpose of embodiments disclosed in the present specification is to provide an apparatus and a method for calculating a drug responsiveness value for a specific gene of organoids by utilizing RNAsep data, which is genetic data.